 Shares of INmune Bio Inc. INMB, -1.09 plummeted 31.4 toward a 22-month low in premarket trading Tuesday, after the Florida-based biotechnology company said it received an email from U.S. Food and Drug Administration, saying that it placed the Investigational New Drug IND application to initiate its Phase 2 trial of its XPro Alzheimers treatment on clinical hold. Also in the email, the FDA requested additional information around Chemistry Manufacturing and Controls CMC regarding the companys newly manufactured XPro1595. 